Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...

D Molecular (FDMT) presented 52-week wet age-related macular degeneration Phase IIb results at this weekend’s Angiogenesis, Exudation, and ...

In the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.

PRISM evaluates 4D-150, a potential backbone therapy designed to provide multi-year sustained delivery of anti-VEGF ...

D Molecular Therapeutics reported 52-week Phase 2b data for 4D-150 in wet AMD, showing sustained visual acuity improvements.

Multiple subcutaneous doses safe and well-tolerated >69% reduction in anti-VEGF intravitreal (IVT) treatment burden in study eyes >67% ...

Bayer submitted an application to the European Medicines Agency (EMA) to expand treatment intervals of up to 6 months with Eylea™ 8 mg (aflibercept 8 mg, ...

On January 29, 2025, the U.S. Court of Appeals for the Federal Circuit affirmed the District Court for the Northern District of West ...

On January 29, 2025, the CAFC issued opinions affirming the preliminary injunctions issued against biosimilars of Regeneron’s EYLEA® ...

Despite these positive outcomes, EyePoint's stock experienced a sharp decline. Cantor Fitzgerald analyst Jennifer Kim commented on the market reaction, stating, "There's nothing here that makes us ...

Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ: NASDAQ:EYPT) fell 21% today, diverging from the company's recent ...

Number 1: In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ...